Key Takeaways
- Shares of Ionis Pharmaceuticals plummeted approximately 20% following disappointing results from the Phase 3 CARDIO-TTRansform study of eplontersen, which missed its primary endpoint
- Collaborative partner AstraZeneca experienced a significant decline of around 9% in response to the trial outcome
- Patients already receiving stabilizer therapyâcomprising the trial’s majorityâshowed no meaningful improvement with eplontersen treatment
- Among participants not using stabilizers, the drug demonstrated a 29% reduction in cardiovascular risk, providing limited encouragement
- Competing biotechnology firms Alnylam and BridgeBio experienced substantial gains as market competition in the ATTR-CM treatment landscape appears to have diminished
Shares of Ionis Pharmaceuticals (IONS) experienced a severe downturn on Thursday, declining between 17% and 20% after the biotechnology company and its collaborator AstraZeneca (AZN) disclosed that eplontersen failed to achieve its primary endpoint in the pivotal Phase 3 CARDIO-TTRansform clinical trial.
Ionis Pharmaceuticals, Inc., IONS
The clinical study evaluated eplontersen’s ability to lower the incidence of cardiovascular mortality and recurrent cardiac events in individuals diagnosed with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) versus placebo treatment across a 140-week observation period. Unfortunately, the investigational therapy fell short of demonstrating statistically significant benefit.
IONS closed Thursday’s session down approximately 17.59%. This decline extends the company’s year-to-date losses to 11.78%, although shares remain elevated roughly 99% compared to the same period last year.
American depositary receipts of AstraZeneca declined about 9% following the announcement, underscoring the strategic importance both pharmaceutical companies had placed on this clinical program.
The trial’s patient demographics revealed that 57% of enrolled participants were already receiving stabilizer medication at baseline, with an additional 24% initiating such therapy during the study period. Within this predominant patient subset, eplontersen failed to demonstrate therapeutic benefit. This outcome presents significant challenges, as stabilizer therapy has become standard practice in contemporary ATTR-CM management.
Limited Efficacy Signal in Treatment-Naive SubgroupâQuestions Remain About Regulatory Path
The data contained one potentially positive finding. Among trial participants who were not receiving stabilizer therapy, eplontersen demonstrated a 29% reduction in the composite endpoint of cardiovascular death and recurrent events. Additionally, the investigational drug achieved robust and sustained reductions in serum transthyretin protein concentrations and successfully met multiple secondary outcome measures.
However, financial analysts remained skeptical that these partial results would support a viable regulatory strategy. Paul Matteis from Stifel characterized any regulatory submission based on these findings as “a stretch.” Neither Ionis nor AstraZeneca has indicated intentions to pursue marketing authorization or initiate additional confirmatory studies.
Chief Executive Officer Brett Monia expressed disappointment while noting the evolving treatment paradigm in which increasing numbers of patients initiate stabilizer therapy prior to clinical trial enrollment. Complete trial data is scheduled for presentation at the European Society of Cardiology Congress in August 2026.
For Ionis, this clinical setback eliminates anticipated revenue streams including profit-sharing arrangements, royalty payments, and future development milestone payments tied to eplontersen’s commercial success in cardiovascular indications.
Competitive Landscape Shifts as Market Players Gain Ground
Shares of Alnylam Pharmaceuticals and BridgeBio both surged by double-digit percentages Thursday. With eplontersen’s prospects in ATTR-CM now uncertain, Alnylam’s Amvuttra appears positioned to maintain its status as the sole RNA-silencing therapeutic option in this indication.
Stifel’s Matteis characterized the development as “a huge positive” for Amvuttra’s competitive positioning. Pfizer’s Vyndamax, currently the market-leading therapy with sales exceeding $6 billion in the previous fiscal year, also stands to capture additional market share with reduced competitive pressure.
Jefferies analyst Michael Leuchten suggested the more substantial concern for AstraZeneca extends beyond lost revenue potential to reputational impact. The pharmaceutical giant had expressed considerable confidence leading into the data readout. “AstraZeneca is meant to be able to have exceptionally good trial design ability,” Leuchten observed.
Wall Street’s consensus rating on IONS prior to Thursday’s announcement stood at Strong Buy, with analysts establishing an average price target of $104.61. These assessments are expected to undergo substantial revision.
Trading activity in IONS reached approximately 3 million shares Thursday, significantly exceeding the three-month average daily volume of 1.86 million shares.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
